Acne therapy redesigned

An innovative treatment option for acne vulgaris – combining clindamycin (1%) and tretinoin (0.025%), – was launched in South Africa in November.

Are probiotics the panacea to antibiotic-associated diarrhoea?

Several studies have shown that probiotics improve the microbial balance of the host and reduce colonisation by pathogenic bacteria.

Keys to successful diabetes management in Ramadan

Ramadan is observed by Muslims worldwide as a month of fasting, prayer, reflection, and community. In 2022 the Holy month of Ramadan starts on the evening of 2 April, lasting 30 days and ending at sundown on 1 May.1

Novo Nordisk launches once-weekly semaglutide in South Africa

Once-weekly semaglutide, a human glucagon-like peptide 1 receptor agonist (GLP1-RA), was launched in South Africa on 21 August 2021.

IV paracetamol in paediatric patients

Indications for the use of IV paracetamol The indications for the use of IV paracetamol include: Treatment of mild to

Contemporary approach to early and advanced BCa – Technical tips learnt that might help you in your practice

The private-based sister unit hosted at Milpark hospital (The Breast Care Centre of Excellence [BCCE]) offers identical multidisciplinary treatment regimes.

Probiotics: conducive to life

It is estimated that the probiotic market will surpass the R800bn mark in the United States by 2025.

Metformin: the oldest, but still the best treatment for T2DM

The discovery of metformin began with the synthesis of galegine-like compounds derived from Gallega officinalis; a plant traditionally employed in Europe as a drug for diabetes treatment for centuries

Real-world data from the ARISE Study

The IDegAsp clinical trial program (BOOST) clinical investigation programme for patients with diabetes assessed the safety and efficacy of once or twice daily administration of IDegAsp using 26-week-long treat-to-target studies.

Long-term efficacy and safety of ruxolitinib in patients with polycythaemia vera

In 2011 the American Food and Drug Administration (FDA) approved ruxolitinib for the treatment of patients with intermediate or high-risk

TPO-RA: Game-changers in the treatment of immune thrombocytopaenia

The incidence of ITP is about 1.6-3.9 per 100 000 patient-years. More women are affected than men. In children, the

Second-generation basal insulins reduce risk of hypoglycaemia and weight gain in patients with T2DM

An estimated 4.2 million adults (20–79 years) died as a result of diabetes and its complications in 2019. This is